- Almac Group has completed two new purpose-built facilities at its headquarters in Craigavon, Northern Ireland in order to meet client demand in commercial manufacturing and packaging as well as peptide production.
- The global expansion investment now totals over £400m / $500m.
Almac Group has announced the completion of two new purpose-built facilities at its headquarters. This large-scale expansion substantially grows operations for two of the Group’s business units, Almac Pharma Services and Almac Sciences. The new facilities are located at the Almac Group’s headquarters in Craigavon, Northern Ireland.
The first project is a 32,000 square feet custom-built high-volume facility for Almac Pharma Services that significantly increases commercial manufacturing and packaging of sachet drug product presentations. The second project is a 28,000 square feet GMP facility that more than doubles peptide API manufacturing capacity for Almac Sciences.
Graeme McBurney, Chief Operating Officer, Almac Group, said: “Today’s announcement of continued expansion ensures that we remain the global leaders in our industry, giving our clients and ultimately patients across the world who benefit from these therapeutics, the best possible offering from Almac.”
